Physician profile
Michael G Saribalas
NPI 1164454211
$1,182,827.56
in general payments reported to CMS, 2019-2025
15 companies · $170K in 2025
The $170K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182K · 2020: $91K · 2021: $133K · 2022: $183K · 2023: $273K · 2024: $149K · 2025: $170K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $364K · Consulting Fee: $143K · Travel and Lodging: $52K · Honoraria: $17K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,000 · Education: $7.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $363,965.00 |
| Consulting Fee | $143,289.50 |
| Travel and Lodging | $51,712.35 |
| Honoraria | $16,538.00 |
| Food and Beverage | $12,650.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,000.00 |
| Education | $7.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $346,733.39 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $220,845.50 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $193,041.40 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $182,651.51 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $86,415.28 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $66,593.92 | 2022-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $52,591.16 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18,027.85 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $15,404.45 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.92 | 2020-2021 | |
| Lundbeck LLC | $151.59 | 2019 | |
| Noctrix Health, INC. | $150.98 | 2025 | Nidra |
| Neurocrine Biosciences, INC. | $20.90 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.67 | 2023 | Qelbree |
| Bausch Health US, LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Saribalas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.